Antiapoptotic Effects of Hydroxychloroquine on Hypoxic–Ischemic Injury in Neonatal Rat Brain: May Hydroxychloroquine Be an Adjuvant Theraphy?

Abstract

Objective Hydroxychloroquine (HCQ) has immunomodulatory, antithrombotic, cardiovascular, antimicrobial, and antineoplastic effects. In this study, we aimed to investigate the antiapoptotic and immunomodulator effects of intraperitoneal HCQ on hypoxic–ischemic (HI) injury in newborn rats.

Study Design Wistar albino rats, 7 to 10 days old, were randomly divided into three groups: hypoxic–ischemic encephalopathy (HIE) group, HIE treated with HCQ group, and Sham group. Left common carotid artery ligation and hypoxia model were performed in HIE and HCQ groups. The HCQ group was treated with 80 mg/kg intraperitoneal HCQ every 24 hours for 3 days, while Sham and HIE groups were given physiological saline. After 72 hours, rats were decapitated and brain tissues were stained with hematoxylin and eosin, TUNEL, and IL-1β for histopathological grading and neuronal cell injury.

Results Neuronal apoptosis was statistically lower in all neuroanatomical areas in the HCQ group compared with the HIE group. IL-1β-stained areas were similar in both HCQ and HIE groups but significantly higher compared with the Sham group. Histopathological grading scores were found to be lower in the HCQ group on the left parietal cortex and hippocampus region.

Conclusion In this study, we have shown for the first time that HCQ treatment decreased apoptosis in HI newborn rat model in both hemispheres. HCQ may be a promising adjuvant therapy in neonatal HIE.

Key Points

• HCQ decreased neuronal apoptosis in the ischemic penumbra of the rat brain.

• HCQ attenuates hypoxia–ischemia-induced brain injury in neonatal rats.

• HCQ has no anti-inflammatory effect on HI injury.

Keywords

hydroxychloroquine - hypoxic–ischemic injury - antiapoptotic - immunomodulator - newborn

Publikationsverlauf

Eingereicht: 29. Januar 2022

Angenommen: 10. März 2022

Accepted Manuscript online:
15. März 2022

Artikel online veröffentlicht:
21. September 2022

• References

• 1 Pin TW, Eldridge B, Galea MP. A review of developmental outcomes of term infants with post-asphyxia neonatal encephalopathy. Eur J Paediatr Neurol 2009; 13 (03) 224-234
• 2 Lundgren C, Brudin L, Wanby AS, Blomberg M. Ante- and intrapartum risk factors for neonatal hypoxic ischemic encephalopathy. J Matern Fetal Neonatal Med 2018; 31 (12) 1595-1601
• 3 Azzopardi D, Strohm B, Marlow N. et al; TOBY Study Group. Effects of hypothermia for perinatal asphyxia on childhood outcomes. N Engl J Med 2014; 371 (02) 140-149
• 4 Costedoat-Chalumeau N, Amoura Z, Duhaut P. et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48 (11) 3207-3211
• 5 Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Antioxidant action of antimalarials. Ann Rheum Dis 1986; 45 (03) 244-248
• 6 Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol 1993; 20 (05) 803-808
• 7 Ruiz A, Rockfield S, Taran N. et al. Effect of hydroxychloroquine and characterization of autophagy in a mouse model of endometriosis. Cell Death Dis 2016; 7 (01) e2059
• 8 Flint J, Panchal S, Hurrell A. et al; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2016; 55 (09) 1693-1697
• 9 Hepping N, Griese M, Lohse P, Garbe W, Lange L. Successful treatment of neonatal respiratory failure caused by a novel surfactant protein C p.Cys121Gly mutation with hydroxychloroquine. J Perinatol 2013; 33 (06) 492-494
• 10 Jon C, Nolan PK, Ekong M, Mosquera RA, Stark JM. SFTPC gene mutation p.R167Q in a premature infant. Pediatr Pulmonol 2014; 49 (03) E66-E68
• 11 Random assignments. Accessed November 27, 2021 at: https://www.graphpad.com/quickcalcs/randomize2/
• 12 Singh J. The national centre for the replacement, refinement, and reduction of animals in research. J Pharmacol Pharmacother 2012; 3 (01) 87-89
• 13 Festing MFW. Design and statistical methods in studies using animal models of development. ILAR J 2006; 47 (01) 5-14
• 14 Rice III JE, Vannucci RC, Brierley JB. The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann Neurol 1981; 9 (02) 131-141
• 15 Vannucci RC, Vannucci SJ. A model of perinatal hypoxic-ischemic brain damage. Ann N Y Acad Sci 1997; 835: 234-249
• 16 Hoque N, Sabir H, Maes E, Bishop S, Thoresen M. Validation of a neuropathology score using quantitative methods to evaluate brain injury in a pig model of hypoxia ischaemia. J Neurosci Methods 2014; 230: 30-36
• 17 Chen X, Hovanesian V, Naqvi S. et al. Systemic infusions of anti-interleukin-1β neutralizing antibodies reduce short-term brain injury after cerebral ischemia in the ovine fetus. Brain Behav Immun 2018; 67: 24-35
• 18 Higgins RD, Raju T, Edwards AD. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Hypothermia Workshop Speakers and Moderators. Hypothermia and other treatment options for neonatal encephalopathy: an executive summary of the Eunice Kennedy Shriver NICHD workshop. J Pediatr 2011; 159 (05) 851-858.e1
• 19 Rocha-Ferreira E, Hristova M. Plasticity in the neonatal brain following hypoxic-ischaemic injury. Neural Plast 2016; 2016: 4901014
• 20 Laptook AR, Shankaran S, Tyson JE. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Effect of therapeutic hypothermia initiated after 6 hours of age on death or disability among newborns with hypoxic-ischemic encephalopathy a randomized clinical trial. JAMA 2017; 318 (16) 1550-1560
• 21 Shankaran S, Laptook AR, Pappas A. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Effect of depth and duration of cooling on death or disability at age 18 months among neonates with hypoxic-ischemic encephalopathy a randomized clinical trial. JAMA 2017; 318 (01) 57-67
• 22 Lorek A, Takei Y, Cady EB. et al. Delayed (“secondary”) cerebral energy failure after acute hypoxia-ischemia in the newborn piglet: continuous 48-hour studies by phosphorus magnetic resonance spectroscopy. Pediatr Res 1994; 36 (06) 699-706
• 23 Hagberg H, Mallard C, Rousset CI, Thornton C. Mitochondria: hub of injury responses in the developing brain. Lancet Neurol 2014; 13 (02) 217-232
• 24 Nakajima W, Ishida A, Lange MS. et al. Apoptosis has a prolonged role in the neurodegeneration after hypoxic ischemia in the newborn rat. J Neurosci 2000; 20 (21) 7994-8004
• 25 Wallace DJ. Antimalarials—the 'real' advance in lupus. Lupus 2001; 10 (06) 385-387
• 26 Todorovic Z, Medic B, Basta-Jovanovic G. et al. Acute pretreatment with chloroquine attenuates renal I/R injury in rats. PLoS One 2014; 9 (03) e92673
• 27 Fang H, Liu A, Dahmen U, Dirsch O. Dual role of chloroquine in liver ischemia reperfusion injury: reduction of liver damage in early phase, but aggravation in late phase. Cell Death Dis 2013; 4 (06) e694
• 28 Nijboer CHA, Heijnen CJ, Groenendaal F, May MJ, van Bel F, Kavelaars A. Strong neuroprotection by inhibition of NF-kappaB after neonatal hypoxia-ischemia involves apoptotic mechanisms but is independent of cytokines. Stroke 2008; 39 (07) 2129-2137
• 29 Tang TT, Lv LL, Pan MM. et al. Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. Cell Death Dis 2018; 9 (03) 351
• 30 Oygür N, Sönmez O, Saka O, Yeğin O. Predictive value of plasma and cerebrospinal fluid tumour necrosis factor-α and interleukin-1 β concentrations on outcome of full term infants with hypoxic-ischaemic encephalopathy. Arch Dis Child Fetal Neonatal Ed 1998; 79 (03) F190-F193
• 31 Koch MW, Zabad R, Giuliani F. et al. Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis. J Neurol Sci 2015; 358 (1-2): 131-137
• 32 Fernández-López D, Faustino J, Derugin N. et al. Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke. Neuroscience 2012; 207: 307-315
• 33 Fox C, Dingman A, Derugin N. et al. Minocycline confers early but transient protection in the immature brain following focal cerebral ischemia-reperfusion. J Cereb Blood Flow Metab 2005; 25 (09) 1138-1149
• 34 Silva JC, Mariz HA, Rocha Jr LF. et al. Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (São Paulo) 2013; 68 (06) 766-771
• 35 Leroux M, Desveaux C, Parcevaux M. et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 2015; 24 (13) 1384-1391
• 36 Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System. Int J Med Sci 2019; 16 (07) 1018-1022
• 37 Hughes G. Hydroxychloroquine: an update. Lupus 2018; 27 (09) 1402-1403
• 38 Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22 (03) 659-661